CV QUEST 2010

A Glimpse into the Future...The Next Decade

Sunday, October 24th, 2010
10:00 am to 12:00 pm

Click here to Register »

Click images for larger preview

Click here to download invitiation »

Four internationally recognized experts shared their forecasts on the practice of cardiovascular medicine in the year 2020. Despite recent advances, heart failure and CAD interventions remain challenged by unacceptably high morbidity and mortality.

The role of primary prevention, drugs and devices in the management of heart failure was discussed. Lifestyle and pharmacologic management was considered as well as their effect on CAD prevention. Environmental and metabolic factors were considered. Treatment for valvular heart disease remains challenging particularly when surgical intervention is required in patients with significant co-morbidities. The future of percutaneous valve replacement as an effective therapy for aortic valve disease was compared with surgical valve replacement. Finally, pharmacogenomics is rapidly expanding, and the promise of tailored therapy has been with us for the past decade. Customized treatments that offer the most effective therapy with the least potential for toxicity was discussed.

Program Faculty:

• Dr. Clyde W. Yancy
• Dr. John G. Webb
• Dr. Robert M. Califf
• Dr. Robert Hegele
• Dr. Milan Gupta
• Dr. Subodh Verma

 

Agenda:

10:00 am - 12:00 pm

Co-Chairs:

Subodh Verma, MD and Milan Gupta, MD

• Opening Remarks
  Milan Gupta, MD – Brampton, ON
• The Heart Failure Beast: Will we conquer it by 2020? Experience
  Clyde Yancy, MD – Dallas, TX
• Intervention vs. Prevention. Will the landscape change by 2020?
  Robert Califf, MD – Durham, NC
• An Obituary to Open Valve Replacement by 2020?
  John Webb, MD – Vancouver, BC
• Pharmacogenomics: Will "smart" therapy come of age by 2020?
  Robert Hegele, MD – London, ON
• Discussion
• Closing Remarks
  Subodh Verma, MD – Toronto, ON

 

CCC 2010 Website »